Repligen Corp

RGEN: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|fGLOCK|SYL?LOCK|<jfn&My#

Repligen Earnings: Double-Digit Revenue Growth and Margin Improvement To Continue in 2026

Repligen reported year-on-year revenue growth of 14% for the quarter and 16% for the year. Full-year adjusted EBITDA margin was 19%, or 50 basis points better than last year. Management's guidance for 2026 includes 9% to 13% organic revenue growth and adjusted EBITDA margin of 20.0% to 20.5%.

Sponsor Center